Eleftherios Mylonakis, MD, PhD, FIDSA

Charles and Anne Duncan Presidential Distinguished Chair, Department of Medicine
Professor of Medicine, Academic Institute
Full Member, Research Institute
Chair, Department of Medicine
Houston Methodist
Weill Cornell Medical College


Biography

Dr. Eleftherios Mylonakis, is Chair of Department of Medicine at Houston Methodist Hospital. Prior to joining HMH, Dr. Mylonakis was Charles C.J. Carpenter Professor of Infectious Disease and. Chief of Infectious Diseases at the Warren Alpert Medical School of Brown University where he was also Professor of Molecular Microbiology and Immunology and Assistant Dean for Longitudinal Medical Research. Prior to his 10 years at Brown, Dr. Mylonakis was Attending Physician at Massachusetts General Hospital and rose through the ranks at Harvard Medical School up to Associate Professor.

Description of Research

Dr. Mylonakis studies host and microbial factors of infection and the discovery of antimicrobial agents. His research encompasses both clinical and laboratory studies and the use of mammalian and invertebrate model hosts systems to identify novel antimicrobial compounds and the elucidation of evolutionarily conserved aspects of microbial virulence and the host response. He has eight patents, has edited five books, and published over 450 articles in the peer-reviewed literature.

Publications

Temporal trends and characteristics associated with racial, ethnic, and sex representation in COVID-19 clinical trials: A systematic review and meta-analysis
Kaczynski, M, Vassilopoulos, A, Vassilopoulos, S, Sisti, A, Benitez, G, Tran, QL, Mylona, EK, Shehadeh, F, Rogers, R & Mylonakis, E 2024, , Contemporary Clinical Trials, vol. 143, 107578. https://doi.org/10.1016/j.cct.2024.107578

In Enterobacterales bacteremia, antipseudomonal b-lactam de-escalation was noninferior to continuation for clinical cure at 3 to 5 d
Ouranos, K & Mylonakis, E 2024, , Annals of Internal Medicine, vol. 177, no. 5, pp. JC52. https://doi.org/10.7326/J24-0030

In adults with post–COVID-19 conditions, a synbiotic preparation, SIM01, alleviated some symptoms at 6 mo
Gotur, D & Mylonakis, E 2024, , Annals of Internal Medicine, vol. 177, no. 4, pp. JC45. https://doi.org/10.7326/J24-0018

Effect of Neutralizing Monoclonal Antibody Treatment on Early Trajectories of Virologic and Immunologic Biomarkers in Patients Hospitalized With COVID-19
for the ACTIV-3/TICO Study Group 2024, , Journal of Infectious Diseases, vol. 229, no. 3, pp. 671-679. https://doi.org/10.1093/infdis/jiad446

Thematic analysis to explore patients' experiences with long COVID-19: A conceptual model of symptoms and impacts on daily lives
Rofail, D, Somersan-Karakaya, S, Choi, JY, Przydzial, K, Zhao, Y, Hussein, M, Norton, TD, Podolanczuk, AJ, Mylonakis, E & Geba, GP 2024, , BMJ open, vol. 14, no. 1. https://doi.org/10.1136/bmjopen-2023-076992

Prevalence of Steatotic Liver Disease Among US Adults with Rheumatoid Arthritis
Vassilopoulos, A, Kalligeros, M, Vassilopoulos, S, Shehadeh, F, Benitez, G, Kaczynski, M, Lazaridou, I, Promrat, K, Wands, JR & Mylonakis, E 2024, , Digestive Diseases and Sciences, vol. 69, no. 3, pp. 989-1003. https://doi.org/10.1007/s10620-023-08225-4

Reply
Kalligeros, M, Mylonakis, E & Noureddin, M 2024, , Clinical Gastroenterology and Hepatology. https://doi.org/10.1016/j.cgh.2024.01.036

Cumulative incidence and mortality rate of cardiovascular complications due to laboratory-confirmed influenza virus infection: A systematic review and meta-analysis
Ouranos, K, Vassilopoulos, S, Vassilopoulos, A, Shehadeh, F & Mylonakis, E 2024, , Reviews in Medical Virology, vol. 34, no. 1, e2497, pp. e2497. https://doi.org/10.1002/rmv.2497

Ten golden rules for optimal antibiotic use in hospital settings: the WARNING call to action
Worldwide Antimicrobial Resistance National/International Network Group (WARNING) Collaborators 2023, , World Journal of Emergency Surgery, vol. 18, no. 1, 50. https://doi.org/10.1186/s13017-023-00518-3

Prevalence and risk factors of nonalcoholic fatty liver disease, high-risk nonalcoholic steatohepatitis, and fibrosis among lean United States adults: NHANES 2017-2020
Kalligeros, M, Vassilopoulos, S, Vassilopoulos, A, Shehadeh, F, Lazaridou, I, Mylonakis, E, Promrat, K & Wands, JR 2023, , Annals of Gastroenterology, vol. 36, no. 6, pp. 670-677. https://doi.org/10.20524/aog.2023.0840

Effect of Neutralizing Monoclonal Antibody Treatment on Early Trajectories of Virologic and Immunologic Biomarkers in Patients Hospitalized With COVID-19.
Mishra, B & Mylonakis, E 2023, , Journal of Infectious Diseases.

Effect of Neutralizing Monoclonal Antibody Treatment on Early Trajectories of Virologic and Immunologic Biomarkers in Patients Hospitalized With COVID-19
ACTIV-3/TICO Study Group 2023, , The Journal of infectious diseases, pp. jiad446. https://doi.org/10.1093/infdis/jiad446

Association of the Streptococcus bovis/Streptococcus equinus Complex With Colorectal Neoplasia: A Systematic Review and Meta-analysis
Ouranos, K, Gardikioti, A, Bakaloudi, DR, Mylona, EK, Shehadeh, F & Mylonakis, E 2023, , Open Forum Infectious Diseases, vol. 10, no. 11, ofad547, pp. ofad547. https://doi.org/10.1093/ofid/ofad547

Association of the Streptococcus bovis/Streptococcus equinus Complex With Colorectal Neoplasia: A Systematic Review and Meta-analysis
Ouranos, K, Gardikioti, A, Bakaloudi, DR, Mylona, EK, Shehadeh, F & Mylonakis, E 2023, , Open Forum Infectious Diseases, vol. 10, no. 11, ofad547. https://doi.org/10.1093/ofid/ofad547

New-Onset Diabetes After COVID-19
Kim, SH, Arora, I, Hsia, DS, Knowler, WC, LeBlanc, E, Mylonakis, E, Pratley, R & Pittas, AG 2023, , Journal of Clinical Endocrinology and Metabolism, vol. 108, no. 11, pp. E1164-E1174. https://doi.org/10.1210/clinem/dgad284

Impact of prior HBV, HAV, and HEV infection on non-alcoholic fatty liver disease
Vassilopoulos, S, Kalligeros, M, Vassilopoulos, A, Shehadeh, F, Benitez, G, Kaczynski, M, Lazaridou, I, Promrat, K, Wands, JR & Mylonakis, E 2023, , Journal of Viral Hepatitis, vol. 30, no. 8, pp. 685-693. https://doi.org/10.1111/jvh.13862

Prevalence and Characteristics of Nonalcoholic Fatty Liver Disease and Fibrosis in People Living With HIV Monoinfection: A Systematic Review and Meta-analysis
Kalligeros, M, Vassilopoulos, A, Shehadeh, F, Vassilopoulos, S, Lazaridou, I, Mylonakis, E, Promrat, K & Wands, JR 2023, , Clinical Gastroenterology and Hepatology, vol. 21, no. 7, pp. 1708-1722. https://doi.org/10.1016/j.cgh.2023.01.001

Antimicrobial Peptides and Small Molecules Targeting the Cell Membrane of Staphylococcus aureus
Ganesan, N, Mishra, B, Felix, LO & Mylonakis, E 2023, , Microbiology and Molecular Biology Reviews, vol. 87, no. 2, pp. e0003722. https://doi.org/10.1128/mmbr.00037-22

In older adults, an Ad26.RSV.preF-RSV preF protein vaccine reduced RSV-related lower respiratory tract disease
Awar, M & Mylonakis, E 2023, , Annals of Internal Medicine, vol. 176, no. 6. https://doi.org/10.7326/J23-0039

In older adults, an AS01E-adjuvanted RSVPreF3 OA vaccine reduced RSV-related lower respiratory tract disease
Awar, M & Mylonakis, E 2023, , Annals of Internal Medicine, vol. 176, no. 6, pp. JC62-JC63. https://doi.org/10.7326/J23-0038